基石藥業-B(02616.HK)合作夥伴布泰吉華獲批治療用於惰性系統性肥大細胞增多症成人患者
基石藥業-B(02616.HK)公布,合作夥伴Blueprint Medicines於5月22日宣布,美國食品藥品監督管理局已批准泰吉華(阿伐替尼片)用於治療惰性系統性肥大細胞增多症成人患者。ISM是一種罕見的血液系統疾病,可廣泛累及多個器官系統並出現一系列異常症狀,顯著影響患者的生活品質。
泰吉華由基石藥業合作夥伴Blueprint Medicines公司開發。基石藥業與Blueprint Medicines公司達成獨家合作和授權協議,獲得了泰吉華在大中華地區的獨家開發和商業化權利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.